NCT04041128View on ClinicalTrials.gov

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

June 15, 2021

Study Completion Date

June 15, 2021

Conditions
Ovarian CancerBreast Cancer
Interventions
DRUG

Lynparza

Lynparza taken orally at a dose of 300mg twice daily for 7 days

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT04041128 - PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | Biotech Hunter | Biotech Hunter